Cantor Fitzgerald analyst Prakhar Agrawal upgraded Madrigal Pharmaceuticals (MDGL) to Overweight from Neutral. The company reported another strong quarter for Rezdiffra, which outperformed high investor expectations, the analyst tells investors in a research note. Cantor says that with better clarity on Madrigal’s 2026 growth and “no major near-term headwinds for the stock,” it is less concerned about the company’s valuation. It believes Madrigal see profitability in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street
- Madrigal Pharmaceuticals reports Q3 EPS ($5.08) vs ($4.92) last year
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms